Decoding 7 Analyst Evaluations For Quest Diagnostics
Portfolio Pulse from Benzinga Insights
Quest Diagnostics (NYSE:DGX) has received varied analyst evaluations over the past quarter, with most analysts maintaining an 'Indifferent' stance. The average 12-month price target has increased by 6.4% to $158.71. Analysts have raised their price targets, reflecting a positive outlook on the company's financial performance, which includes strong net margins and effective debt management.
October 07, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Quest Diagnostics has received a mix of analyst ratings, predominantly 'Indifferent', with a notable increase in the average price target to $158.71. Analysts have raised their price targets, indicating a positive outlook on the company's financial performance.
The increase in the average price target and the fact that several analysts have raised their price targets suggest a positive sentiment towards Quest Diagnostics. The company's strong financial metrics, such as net margin and debt management, further support this outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100